Dispenzieri Angela, Rajkumar S Vincent, Gertz Morie A, Fonseca Rafael, Lacy Martha Q, Bergsagel P Leif, Kyle Robert A, Greipp Philip R, Witzig Thomas E, Reeder Craig B, Lust John A, Russell Stephen J, Hayman Suzanne R, Roy Vivek, Kumar Shaji, Zeldenrust Steven R, Dalton Robert J, Stewart A Keith
Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA.
Mayo Clin Proc. 2007 Mar;82(3):323-41. doi: 10.4065/82.3.323.
Multiple myeloma is a neoplastic plasma cell dyscrasia that on a yearly basis affects nearly 17,000 individuals and kills more than 11,000. Although no cure exists, many effective treatments are available that prolong survival and improve the quality of life of patients with this disease. The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, beta2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment.
多发性骨髓瘤是一种肿瘤性浆细胞异常增生症，每年影响近17,000人，导致超过11,000人死亡。尽管无法治愈，但有许多有效的治疗方法可以延长这种疾病患者的生存期并改善其生活质量。本共识的目的是为新诊断的骨髓瘤患者提供一种简化的、基于证据的决策算法。在缺乏证据的情况下，我们梅奥诊所的18位骨髓瘤专家团队就通常可推荐的治疗方法达成了共识。我们策略的重点围绕风险分层。尽管多年来已确定了众多风险因素，包括年龄、肿瘤负荷、肾功能、乳酸脱氢酶、β2微球蛋白和血清白蛋白，但我们小组现在认可并支持将基因分层和患者功能状态用于治疗。
